Vaccine value profile for invasive non-typhoidal Salmonella disease
Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNT...
Saved in:
| Published in | Vaccine Vol. 42; no. 19; pp. S101 - S124 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
25.07.2024
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2024.04.045 |
Cover
| Abstract | Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and ‘African-restricted clades’ of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future.
The “Vaccine Value Profile” (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally.
This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a “Full Vaccine Value Assessment” that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. |
|---|---|
| AbstractList | Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and 'African-restricted clades' of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future. The "Vaccine Value Profile" (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally. This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a "Full Vaccine Value Assessment" that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and 'African-restricted clades' of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future. The "Vaccine Value Profile" (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally. This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a "Full Vaccine Value Assessment" that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and ‘African-restricted clades’ of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future. The “Vaccine Value Profile” (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally. This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a “Full Vaccine Value Assessment” that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and ‘African-restricted clades’ of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future.The “Vaccine Value Profile” (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally.This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a “Full Vaccine Value Assessment” that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. AbstractInvasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa (sSA), predominantly among immune-naïve infants and young children, including those with recognized comorbidities such as HIV infection. iNTS disease is primarily caused by Salmonella enterica serovar Typhimurium sequence type (ST) 313 and ‘African-restricted clades’ of Salmonella Enteritidis ST11 that have emerged across the African continent as a series of epidemics associated with acquisition of new antimicrobial resistance. Due to genotypes with a high prevalence of antimicrobial resistance and scarcity of therapeutic options, these NTS serovars are designated by the World Health Organization as a priority pathogen for research and development of interventions, including vaccines, to address and reduce NTS associated bacteremia and meningitis in sSA. Novel and traditional vaccine technologies are being applied to develop vaccines against iNTS disease, and the results of the first clinical trials in the infant target population should become available in the near future. The “Vaccine Value Profile” (VVP) addresses information related predominantly to invasive disease caused by Salmonella Enteritidis and Salmonella Typhimurium prevalent in sSA. Information is included on stand-alone iNTS disease candidate vaccines and candidate vaccines targeting iNTS disease combined with another invasive serotype, Salmonella Typhi, that is also common across sSA. Out of scope for the first version of this VVP is a wider discussion on either diarrheagenic NTS disease (dNTS) also associated with Salmonella Enteritidis and Salmonella Typhimurium or the development of a multivalent Salmonella vaccines targeting key serovars for use globally. This VVP for vaccines to prevent iNTS disease is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. Future versions of this VVP will be updated to reflect ongoing activities such as vaccine development strategies and a “Full Vaccine Value Assessment” that will inform the value proposition of an iNTS disease vaccine. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the World Health Organization African Region. All contributors have extensive expertise on various elements of the iNTS disease VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. |
| Author | Owusu-Dabo, Ellis Marchello, Christian S. Sikorski, Michael J. Crump, John A. Martin, Laura B. Mogasale, Vittal Tack, Bieke Nyirenda, Tonney |
| Author_xml | – sequence: 1 givenname: Laura B. orcidid: 0000-0001-7146-1283 surname: Martin fullname: Martin, Laura B. email: LauraBMartin@vacc4impact.science organization: Independent Consultant, USA – sequence: 2 givenname: Bieke surname: Tack fullname: Tack, Bieke email: btack@itg.be organization: Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Belgium and Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium – sequence: 3 givenname: Christian S. surname: Marchello fullname: Marchello, Christian S. email: Christian.Marchello@otago.ac.nz organization: Centre for International Health, University of Otago, New Zealand – sequence: 4 givenname: Michael J. orcidid: 0000-0002-3811-7285 surname: Sikorski fullname: Sikorski, Michael J. email: michael.sikorski@som.umaryland.edu organization: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 5 givenname: Ellis surname: Owusu-Dabo fullname: Owusu-Dabo, Ellis email: Eowusu-Dabo.chs@knust.edu.gh organization: Kwame Nkrumah University of Science and Technology, Ghana – sequence: 6 givenname: Tonney surname: Nyirenda fullname: Nyirenda, Tonney email: TNyirenda@medcol.mw organization: University of Malawi - College of Medicine, Malawi – sequence: 7 givenname: Vittal surname: Mogasale fullname: Mogasale, Vittal email: mogasalev@who.int organization: International Vaccine Institute, Republic of Korea – sequence: 8 givenname: John A. orcidid: 0000-0002-4529-102X surname: Crump fullname: Crump, John A. email: john.crump@otago.ac.nz organization: Centre for International Health, University of Otago, New Zealand |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39003017$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk9r3DAQxUVJaDZpP0KLoZdevB1JlmxR2lKW_gkEckhbehOyNKbaau2NZBv229fubnpYKBsY0OX33jzNzCU5a7sWCXlBYUmByjfr5Wis9S0uGbBiCXOJJ2RBq5LnTNDqjCyAySIvKPy8IJcprQFAcKqekguuADjQckFWP_Yu2WjCgNk2do0PmDVdzHw7muRHzKbOeb_b_uq8MyG7M2EzRQnBZM4nNAmfkfPGhITPD-8V-f7507fV1_zm9sv16uNNbgUXfU4ViFIIxYxTysma0YLLGi2rRV1a7pqGSVZV1jiqGDNYysZxWYBiUpbOIb8ir_e-U8r7AVOvNz7ZOUmL3ZA0p4LLihYCTqNQKiUkZWJCXx2h626I7fSRv1RZcUariXp5oIZ6g05vo9-YuNMPk5yAt3vAxi6liI22vje979o-Gh80BT3vTa_1YW963puGueYQ4kj90OCU7sNeh9PcR49RJ-uxteh8RNtr1_mTDu-PHGzwrbcm_MYdpn-zoDoxDfpuvqn5pFgBUJQwG7z7v8EjAvwBmSrcbg |
| CitedBy_id | crossref_primary_10_12677_acm_2025_151220 crossref_primary_10_1016_j_vaccine_2025_126913 |
| Cites_doi | 10.3201/eid2111.150624 10.1080/14760584.2016.1189330 10.1093/infdis/jiz587 10.1093/cid/ciy1108 10.1017/S0950268823001693 10.1371/journal.pntd.0007485 10.1172/JCI33998 10.1016/j.vaccine.2015.02.027 10.1080/07853890.2017.1421320 10.1371/journal.pntd.0008121 10.1016/j.jinf.2021.06.029 10.1126/science.1180346 10.1186/s12941-016-0147-z 10.1016/j.vaccine.2015.04.013 10.1016/S1201-9712(02)90109-8 10.1016/S1473-3099(17)30753-3 10.1016/S2214-109X(17)30022-0 10.1016/j.jim.2012.10.005 10.1128/CVI.00115-14 10.1038/ng.2423 10.1128/ecosalplus.esp-0007-2018 10.1186/s12879-016-1604-1 10.1136/bmjopen-2023-080501 10.1017/S0950268810001615 10.1073/pnas.0910497107 10.1371/journal.pntd.0002487 10.1093/infdis/jiu045 10.1093/cid/ciz715 10.1371/journal.pntd.0004604 10.1038/s41598-019-47359-2 10.1136/bmjopen-2023-072938 10.1038/s41598-021-01030-x 10.1097/00006454-200004000-00010 10.1186/ISRCTN51750695 10.1097/01.inf.0000202066.02212.ff 10.4161/hv.29054 10.3390/vaccines11111671 10.1093/cid/ciaa1153 10.1016/S1473-3099(21)00615-0 10.1080/02724930092057 10.1101/gr.091017.109 10.3201/eid2701.190676 10.1016/j.micinf.2017.11.014 10.1097/00002030-200208160-00009 10.1086/529146 10.1186/1741-7015-12-31 10.1016/j.gheart.2014.08.009 10.1128/CMR.00002-15 10.15620/cdc:82532 10.1093/cid/ciy898 10.3201/eid2011.141175 10.3201/eid2106.140999 10.1371/journal.pntd.0008682 10.1371/journal.pntd.0006027 10.1093/cid/ciaa514 10.1016/j.vaccine.2015.02.030 10.1177/004947550403400404 10.1016/j.vaccine.2015.04.028 10.1016/S2214-109X(24)00092-5 10.1093/cid/civ675 10.4269/ajtmh.20-1453 10.1016/S1473-3099(19)30418-9 10.1093/cid/cit798 10.1093/cid/ciy386 10.1186/s12916-023-02929-0 10.1136/bmj.c1350 10.1371/journal.pntd.0008440 10.1128/ecosalplus.esp-0010-2016 10.1093/cid/civ711 10.1080/21645515.2020.1785791 10.1371/journal.pone.0172163 10.1080/00365540410020802a 10.1038/nri3858 10.1186/1475-2875-13-400 10.1186/s12879-021-06198-1 10.1093/cid/ciz608 10.1038/s41598-019-56688-1 10.1016/S0140-6736(21)02724-0 10.1080/14737159.2020.1724784 10.1093/cid/civ674 10.1128/CVI.00106-16 10.1007/82_2021_246 10.1186/s12916-020-01652-4 10.1371/journal.pntd.0007782 10.3389/fmed.2019.00205 10.1080/14760584.2023.2270596 10.1093/infdis/jiy501 10.1371/journal.pntd.0003979 10.1016/S0140-6736(09)61374-X 10.1016/j.vaccine.2016.03.072 10.1136/bmjopen-2023-076477 10.1093/cid/civ673 10.1093/cid/civ709 10.1128/CVI.00057-17 10.1093/cid/civ685 10.1093/cid/civ691 10.1371/journal.pntd.0005283 10.1093/cid/ciaa1321 10.12688/wellcomeopenres.19012.1 |
| ContentType | Journal Article |
| Copyright | 2024 Copyright © 2024. Published by Elsevier Ltd. Copyright Elsevier Limited Jul 25, 2024 |
| Copyright_xml | – notice: 2024 – notice: Copyright © 2024. Published by Elsevier Ltd. – notice: Copyright Elsevier Limited Jul 25, 2024 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2024.04.045 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 1873-2518 |
| EndPage | S124 |
| ExternalDocumentID | 39003017 10_1016_j_vaccine_2024_04_045 S0264410X24004705 1_s2_0_S0264410X24004705 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Africa South of the Sahara Zambia Nigeria Kenya Africa Sub-Saharan Africa |
| GeographicLocations_xml | – name: Africa South of the Sahara – name: Nigeria – name: Africa – name: Kenya – name: Zambia – name: Sub-Saharan Africa |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP 6I. AAFTH AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION CGR CUY CVF ECM EFLBG EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c535t-190575592ad99d6b21436bec2b5b7c3dff26288cad1922ae76fd364092667dde3 |
| IEDL.DBID | AIKHN |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Fri Sep 05 06:31:17 EDT 2025 Thu Sep 04 19:41:14 EDT 2025 Wed Aug 13 02:38:06 EDT 2025 Sat Sep 06 11:15:16 EDT 2025 Tue Jul 01 01:07:20 EDT 2025 Thu Apr 24 23:06:52 EDT 2025 Tue Dec 03 03:45:16 EST 2024 Sun Feb 23 10:19:35 EST 2025 Tue Aug 26 16:34:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Keywords | sSA VIS AVAREF PDVAC SAGE NARMS DT VVP QC FERG TSCV Pf WaSH Tfh SETA UN MDR Th17 CMI WHO IL IM AMR MIC GMP IV STm UNICEF US CDC EU R&D NITAG IVB MAPS Vaccine value profile STy IVI ELISA IgA PPC DCVMN ECBI RITAG TCV dNTS IgG NTS Invasive non-typhoidal Salmonella CFR IgM LPS C3 GLASS SBA DALY IHME TPP CHIM LANT FVVA GMMA SEn PTRS ST HIC OR PAHO RF CI Treg XDR Vaccine COPS CD4 HIV iNTS CD8 LMIC iTPP VAF NRA EPI PO Full value of vaccine assessment National regulatory authority Global Anti-Microbial Resistance and Use Surveillance System of WHO Intramuscular administration Per os, oral administration T-follicular helper cell Multiple antigen presenting system High-income country United States Centers for Disease Control and Prevention World Health Organization Case fatality ratio Minimum inhibitory concentration Human immunodeficiency virus United Nations Children's Fund (originally known as the United Nations International Children's Emergency Fund) Core O-polysaccharide of LPS Intervention target product profile Cell-mediated immunity Serum bactericidal activity Non-typhoidal Salmonella Preferred product characteristics Water, sanitation and hygiene International Vaccine Institute, (Seoul,South Korea) Controlled human infection model Expanded Programme on Immunization European Union Sequnce type Intravenous administration United Nations Vaccine investment strategy, Gavi Diarrheagenic non-typhoidal Salmonella Generalized modules for membrane antigens Salmonella enterica serovar Typhimurium, Salmonella Typhimurium Lipopolysaccharide Pan American Health Organization revolving fund Salmonella enterica serovar Enteritidis, Salmonella Enteritidis Trivalent Salmonella conjugate vaccine Typhoid conjugate vaccine ( Salmonella Typhi Vi-polysaccharide conjugated to a carrier protein) Product Development for Vaccines Advisory Committeeof WHO Cluster of differentiation 4 National Antimicrobial Resistance Monitoring System of U.S. Food and Drug Administration Quality control Regulatory T cell African Vaccine Regulatory Forum Cluster of differentiation 8 Disability-adjusted life years Developing Countries Vaccine Manufacturers Network Immunoglobulin M Good manufacturing practice Extensive drug resistance Immunoglobulin G Interleukin Vaccine value profile, developed by WHO Live attenuated non-transmissible Immunoglobulin A Plasmodium falciparum, P. falciparum Research and development National Immunization Technical Advisory Groups of WHO sub-Saharan Africa Regional Immunization Technical Advisory Group of WHO Target product profile Foodborne Disease Burden Epidemiology Research Group of WHO Salmonella enterica serovar Typhi, Salmonella Typhi Enzyme-linked immunosorbent assay Probability of technical and regulatory success Diphtheria toxoid Institute of Health Metrics and Evaluation, University of Washington Low- and middle-income country Strategic Advisory Group of Experts on Immunization of WHO Multidrug resistant Complement component 3 T-helper 17 cell Confidence interval Severe typhoid in Africa program Immunization, Vaccines and Biologicals department of WHO Odds ratio Antimicrobial resistance Value attribution framework, developed by WHO Expert Committee on Biological Standarization |
| Language | English |
| License | Copyright © 2024. Published by Elsevier Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c535t-190575592ad99d6b21436bec2b5b7c3dff26288cad1922ae76fd364092667dde3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4529-102X 0000-0001-7146-1283 0000-0002-3811-7285 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X24004705 |
| PMID | 39003017 |
| PQID | 3079783218 |
| PQPubID | 105530 |
| ParticipantIDs | proquest_miscellaneous_3153681450 proquest_miscellaneous_3079956125 proquest_journals_3079783218 pubmed_primary_39003017 crossref_citationtrail_10_1016_j_vaccine_2024_04_045 crossref_primary_10_1016_j_vaccine_2024_04_045 elsevier_sciencedirect_doi_10_1016_j_vaccine_2024_04_045 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X24004705 elsevier_clinicalkey_doi_10_1016_j_vaccine_2024_04_045 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-25 |
| PublicationDateYYYYMMDD | 2024-07-25 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Goh, MacLennan (b0520) 2013; 387 controlled human infection model: report from a consultation group workshop, 05 July 2022, London, UK. Wellcome Open Res 2023;8:111. doi:10.12688/wellcomeopenres.19012.2. disease in sub-Saharan Africa. In: Abstract presented at: Vaccines Against Wellcome. Full value of vaccines assessment for invasive non-typhoidal Wellcome. Process development and preclinical toxicity study for trivalent Typhi/iNTS vaccine. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx Wellcome Trust, Bill & Melinda Gates Foundation. Meeting report: non-typhoidal (NTS) CHIM workshop, 27 January 2021. Heyderman RS, Crump JA, on behalf of the conference attendees. Invasive Salmonella in Africa consensus meeting 2014, Blantyre, Malawi. Emerg Infect Dis. 2015 Nov; 21(11): e150624. Hagedoorn, Murthy, Birkhold, Marchello, Crump (b0220) 2023; 152 van Griensven, Cnops, De Weggheleire, Declercq, Bottieau (b0430) 2020; 7 HIC-Vac. HIC-Vac annual meeting: 18-19 November 2021. [report] Aldrich, Hartman, Feasey, Chattaway, Dekker, Al-Emran (b0045) 2019; 13 vaccines; Virtual; 22 and 24 September 2021. Levine MM, Chen WH, Barnes R, Sikorski M, Tennant S, Simon R, et al. Phase 1 trial of a trivalent MacLennan, Gondwe, Msefula, Kingsley, Thomson, White (b0180) 2008; 118 Bebell, Muiru (b0360) 2014; 9 Nadjm, Amos, Mtove, Ostermann, Chonya, Wangai (b0405) 2010; 340 Necchi, Saul, Rondini (b0535) 2017; 12 Ramasamy M, Ramasamy M, Hanumunthadu BK, Oxford Vaccine Group. Molyneux, Walsh, Malenga, Rogerson, Molyneux (b0145) 2000; 20 Vojtek, Dieussaert, Doherty, Franck, Hanssens, Miller (b0485) 2018; 50 Tacconelli, Carrara, Savoldi, Harbarth, Mendelson, Monnet (b0240) 2018; 18 Hausdorff WP, Scheele S. If we build it, will they come? Assessing the full public health value of enteric vaccines. Abstract presented at: Vaccines Against Hanumunthadu, Kanji, Owino, Ferreira Da Silva, Robinson, White (b0645) 2023; 13 Canals R. Development of GMMA-based vaccines against iNTS: current status. In: Abstract presented at: 13th International Conference on Typhoid & Other Invasive Salmonelloses; Kigali, Rwanda; 5–7 December 2023. (NTS) and broadly protective Invasive Disease Collaborators. The global burden of non-typhoidal Oneko, Kariuki, Muturi-Kioi, Otieno, Otieno, Williamson (b0465) 2015; 61 Marchello, Birkhold, Crump (b0125) 2022; 22 [accessed 31 December 2021]. Walsh, Phiri, Graham, Molyneux, Molyneux (b0285) 2000; 19 Levine M, Chen W, Barnes R, Sikorski M, Tennant S, Simon R, et al. Phase 1 trial of a trivalent Struck, Zimmermann, Krumkamp, Lorenz, Jacobs, Rieger (b0440) 2020; 221 and ETEC (VASE) Virtual Symposium; 28 September 2021. (CHANTS) Consortium: Development of a non-typhoidal conjugate vaccine to prevent invasive non-typhoidal Feasey, Cain, Msefula, Pickard, Alaerts, Aslett (b0460) 2014; 20 infections. Wellcome Trust Innov Awards - Grants Funded 2021. Feasey, Masesa, Jassi, Faragher, Mallewa, Mallewa (b0105) 2015; 61 De Micco, Maraghini, Spadafina (b0695) 2022; 27 Tack, Vita, Phoba, Mbuyi-Kalonji, Hardy, Barbé (b0140) 2021; 11 World Health Organization. PDVAC (virtual) meeting on invasive non-typhoidal Hutubessy, Lauer, Giersing, Sim, Jit, Kaslow (b0490) 2023; 21 Kariuki, Onsare (b0050) 2015; 61 Watson, Edmunds (b0390) 2015; 33 Smith, Smith, Rydlova, Varro, Hinton, Gordon, Choy, Liu, Pollard, Chiu, Cooke, Gibani (b9000) 2024 Jan 10; 14 Tack, Vanaenrode, Verbakel, Toelen, Jacobs (b0275) 2020; 18 Parsons, Humphrey, Salisbury, Mikoleit, Hinton, Gordon (b0060) 2013; 7 World Health Organization. Assessing the programmatic suitability of vaccine candidates for WHO prequalification. WHO/IVB/12.10. 2012. and ETEC (VASE) Virtual Symposium; 30 September 2021. Lu Y, Roy E, Zhang F, Hirsch A, MacLennan C, Malley R. MAPS vaccine against Marks, von Kalckreuth, Aaby, Adu-Sarkodie, El Tayeb, Ali (b0015) 2017; 5 Skidmore, Canals, Ramasamy (b0640) 2023; 22 Nyirenda, Nyirenda, Tembo, Storm, Dube, Msefula (b0215) 2017; 24 Wellcome. Live attenuated non-transmissible Qureshi, Naveed, Yousafzai, Ahmad, Ansari, Lohana (b0475) 2020; 14 O’Neill J. Tackling drug-resistant infections globally: final report and recommendation; 2016. Jacobs, Hardy, Semret, Lunguya, Phe, Affolabi (b0350) 2019; 6 MacLennan, Msefula, Gondwe, Gilchrist, Pensulo, Mandala (b0135) 2017; 11 Hausdorff, Madhi, Kang, Kaboré, Bayona, Giersing (b9020) 2024; 12 Mogasale, Ramani, Mogasale, Park (b0415) 2016; 15 Wellcome Trust, Boston Consulting Group. Vaccines to tackle drug resistant infections: an evaluation of R&D opportunities; 2018. Crump, Heyderman (b0380) 2015; 61 Schloesser, Schaefer, Groll (b0150) 2004; 36 Canals R, Cappelletti E, Necchi F, Vitali C, Micoli F, Martin L, et al. An effective, affordable and sustainable vaccine to tackle Kariuki, Mbae, Onsare, Kavai, Wairimu, Ngetich (b0685) 2019; 68 Dailey, Elbeik, Holodniy (b0435) 2020; 20 Marchello, Fiorino, Pettini, Crump (b0130) 2021; 83 Lee, Mogasale, Marks, Kim (b0055) 2021; 21 H2020. Vacc-iNTS: Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa. CORDIS - EU research projects under Horizon 2020 (2014–2020). Appiah, Mpimbaza, Lamorde, Freeman, Kajumbula, Salah (b0290) 2021; 105 Jeon, Pak, Im, Owusu-Dabo, Adu-Sarkodie, Gassama Sow (b0480) 2018; 67 infections in infants and young children in sub-Saharan Africa. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx Kariuki SM. Nontyphoidal Manore, Graham, Carr, Feryn, Jakhar, Mukundan (b0425) 2019; 9 Keddy, Sooka, Musekiwa, Smith, Ismail, Tau (b0155) 2015; 61 Carias, Walters, Wefula, Date, Swerdlow, Vijayaraghavan (b0375) 2015; 33 Okoro, Kingsley, Connor, Harris, Parry, Al-Mashhadani (b0040) 2012; 44 Post, Diallo, Guiraud, Lompo, Tahita, Maltha (b0065) 2019; 13 Boerth, Gong, Roffler, Thompson, Song, Malley (b0615) 2023; 11 Murray, Ikuta, Sharara, Swetschinski, Robles Aguilar, Gray (b0265) 2022; 399 [accessed 30 December 2021]. (iNTS) — Level 3 cause; 2019. Mastroeni, Rossi (b0170) 2016; 15 Falay, Kuijpers, Phoba, De Boeck, Lunguya, Vakaniaki (b0280) 2016; 16 conjugate vaccine to prevent invasive Park, Toy, Cruz Espinoza, Panzner, Mogeni, Im (b0030) 2019; 69 Nyirenda, Mandala, Gordon, Mastroeni (b0175) 2018; 20 MacLennan, Martin, Micoli (b0165) 2014; 10 [accessed 27 November 2023]. Gordon, Graham, Walsh, Wilson, Phiri, Molyneux (b0270) 2008; 46 World Health Organization. Framework on value of non-typhoidal Collier, Deng, Adam, Benedict, Beshearse, Blackstock (b0255) 2021; 27 Boyd, Tennant, Saague, Simon, Muhsen, Ramachandran (b0525) 2014; 21 World Health Organization. WHO meeting report: Expert consultation on scope of non-typhoidal Institute for Health Metrics and Evaluation, University of Washington. GBD Results Tool | GHDx. Global Health Data Exchange; 2021. Gilchrist, MacLennan, Hill (b0200) 2015; 15 Tennant, MacLennan, Simon, Martin, Khan (b0590) 2016; 34 Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. doi:10.15620/cdc:82532. Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America; 2019. World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring; 2014. Baliban, Lu, Malley (b0600) 2020; 71 disease in sub-Saharan Africa. In: Abstract presented at: 12th International Conference on Typhoid & Other Invasive Salmonelloses; Virtual; 6–8 December 2021. Institute for Health Metrics and Evaluation. Invasive non-typhoidal Ramachandran, Boyd, MacSwords, Higginson, Simon, Galen (b0545) 2016; 23 PEDVAC-iNTS: Pediatric phase I/II age de-escalation dose-finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa. In: New drugs and vaccines for priority pathogens in antimicrobial resistance – 2019. Ao, Feasey, Gordon, Keddy, Angulo, Crump (b0005) 2015; 21 vaccines. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx Baker, Hombach, Marks (b0010) 2016; 62 World Health Organization. Requests to initiate new WHO reference material projects for vaccines and related substances. WHO/BS/2015.2272. Geneva; 2015. Ramani, Park, Toy, Panzner, Mogeni, Im (b0335) 2019; 69 World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) 2015. vaccine study in Oxford; 2022. doi:10.1186/ISRCTN51750695. In: Ahmed R, Akira S, Casadevall A, Galan JE, Garcia-Sastre A, Rappuoli R, et al, editors. Current topics in microbiology and immunology. Berlin, Heidelberg: Springer; 2021. doi:10.1007/82_2021_246. Gondwe, Molyneux, Goodall, Graham, Mastroeni, Drayson (b0185) 2010; 107 de Alwis, Tu, Quynh, Thompson, Anders, Van Thuy (b0190) 2019; 219 Rosanova, Paganini, Bologna, Lopardo, Ensinck (b0330) 2002; 6 MacLennan, Gilchrist, Gordon, Cunningham, Cobbold, Goodall (b0210) 2010; 328 infections and typhoid fever in sub-Saharan Africa. In: Abstract presented at: 12th international conference on typhoid & other invasive salmonelloses; Virtual; 6–8 December 2021. [accessed 9 May 2022]. Galen, Buskirk, Tennant, Pasetti (b0595) 2016; 7 Gibani, Jin, Darton, Pollard (b0560) 2015; 61 (iNTS) vaccines; Virtual; 29 November–1 December 2021. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) Report: 2021. Andrews, Vaidya, Saha, Yousafzai, Hemlock, Longley (b0400) 2020; 71 Feasey, Everett, Faragher, Roca-Feltrer, Kang’ombe, Denis (b0100) 2015; 9 Santos, Roberts, Cook, Simons, Sheehan, Lane (b0690) 2011; 139 World Health Organization: Control and Response Strategies, Surveillance, Prevention and Control (SPC) Team. Global research agenda for antimicrobial resistance in human health: policy brief. World Health Organization; 2023. World Health Organization. WHO meeting report: expert consultation on invasive non-typhoidal Brent, Oundo, Mwangi, Ochola, Lo Piccini (10.1016/j.vaccine.2024.04.045_b0110) 2020; 16 Mogasale (10.1016/j.vaccine.2024.04.045_b0415) 2016; 15 10.1016/j.vaccine.2024.04.045_b0340 Date (10.1016/j.vaccine.2024.04.045_b0385) 2015; 33 Molyneux (10.1016/j.vaccine.2024.04.045_b0145) 2000; 20 10.1016/j.vaccine.2024.04.045_b0580 Goh (10.1016/j.vaccine.2024.04.045_b0520) 2013; 387 Tacconelli (10.1016/j.vaccine.2024.04.045_b0240) 2018; 18 Nadjm (10.1016/j.vaccine.2024.04.045_b0405) 2010; 340 10.1016/j.vaccine.2024.04.045_b0610 Feasey (10.1016/j.vaccine.2024.04.045_b0460) 2014; 20 10.1016/j.vaccine.2024.04.045_b0575 Manore (10.1016/j.vaccine.2024.04.045_b0425) 2019; 9 Skidmore (10.1016/j.vaccine.2024.04.045_b0640) 2023; 22 Keddy (10.1016/j.vaccine.2024.04.045_b0155) 2015; 61 Dailey (10.1016/j.vaccine.2024.04.045_b0435) 2020; 20 Gibani (10.1016/j.vaccine.2024.04.045_b0560) 2015; 61 Post (10.1016/j.vaccine.2024.04.045_b0065) 2019; 13 Nyirenda (10.1016/j.vaccine.2024.04.045_b0215) 2017; 24 10.1016/j.vaccine.2024.04.045_b0570 Kaufhold (10.1016/j.vaccine.2024.04.045_b0395) 2019; 68 Murray (10.1016/j.vaccine.2024.04.045_b0265) 2022; 399 MacLennan (10.1016/j.vaccine.2024.04.045_b0135) 2017; 11 MacLennan (10.1016/j.vaccine.2024.04.045_b0180) 2008; 118 10.1016/j.vaccine.2024.04.045_b0445 Necchi (10.1016/j.vaccine.2024.04.045_b0535) 2017; 12 10.1016/j.vaccine.2024.04.045_b0565 10.1016/j.vaccine.2024.04.045_b0320 Kariuki (10.1016/j.vaccine.2024.04.045_b0685) 2019; 68 Aldrich (10.1016/j.vaccine.2024.04.045_b0045) 2019; 13 10.1016/j.vaccine.2024.04.045_b0605 Marks (10.1016/j.vaccine.2024.04.045_b0015) 2017; 5 Hagedoorn (10.1016/j.vaccine.2024.04.045_b0220) 2023; 152 Biggs (10.1016/j.vaccine.2024.04.045_b0095) 2014; 58 Andrews (10.1016/j.vaccine.2024.04.045_b0420) 2015; 33 Qureshi (10.1016/j.vaccine.2024.04.045_b0475) 2020; 14 10.1016/j.vaccine.2024.04.045_b0120 Tack (10.1016/j.vaccine.2024.04.045_b0140) 2021; 11 Gondwe (10.1016/j.vaccine.2024.04.045_b0185) 2010; 107 10.1016/j.vaccine.2024.04.045_b0115 10.1016/j.vaccine.2024.04.045_b0635 Marchello (10.1016/j.vaccine.2024.04.045_b0125) 2022; 22 Collier (10.1016/j.vaccine.2024.04.045_b0255) 2021; 27 10.1016/j.vaccine.2024.04.045_b0355 10.1016/j.vaccine.2024.04.045_b0630 Ao (10.1016/j.vaccine.2024.04.045_b0005) 2015; 21 10.1016/j.vaccine.2024.04.045_b0235 10.1016/j.vaccine.2024.04.045_b0510 Tack (10.1016/j.vaccine.2024.04.045_b0275) 2020; 18 Thindwa (10.1016/j.vaccine.2024.04.045_b0310) 2019; 9 Carias (10.1016/j.vaccine.2024.04.045_b0375) 2015; 33 Marchello (10.1016/j.vaccine.2024.04.045_b0130) 2021; 83 Oneko (10.1016/j.vaccine.2024.04.045_b0465) 2015; 61 10.1016/j.vaccine.2024.04.045_b0515 Feasey (10.1016/j.vaccine.2024.04.045_b0105) 2015; 61 Jeon (10.1016/j.vaccine.2024.04.045_b0480) 2018; 67 Feasey (10.1016/j.vaccine.2024.04.045_b0100) 2015; 9 10.1016/j.vaccine.2024.04.045_b0230 10.1016/j.vaccine.2024.04.045_b0470 Hanumunthadu (10.1016/j.vaccine.2024.04.045_b0645) 2023; 13 Kariuki (10.1016/j.vaccine.2024.04.045_b0050) 2015; 61 Parsons (10.1016/j.vaccine.2024.04.045_b0060) 2013; 7 Mastroeni (10.1016/j.vaccine.2024.04.045_b0170) 2016; 15 Crump (10.1016/j.vaccine.2024.04.045_b0075) 2021; 73 10.1016/j.vaccine.2024.04.045_b0500 10.1016/j.vaccine.2024.04.045_b0345 Struck (10.1016/j.vaccine.2024.04.045_b0440) 2020; 221 10.1016/j.vaccine.2024.04.045_b0620 10.1016/j.vaccine.2024.04.045_b0585 Bornstein (10.1016/j.vaccine.2024.04.045_b0370) 2017; 11 Kariuki (10.1016/j.vaccine.2024.04.045_b0070) 2020; 14 Gordon (10.1016/j.vaccine.2024.04.045_b0080) 2002; 16 Lee (10.1016/j.vaccine.2024.04.045_b0055) 2021; 21 10.1016/j.vaccine.2024.04.045_b0625 Brent (10.1016/j.vaccine.2024.04.045_b0085) 2006; 25 10.1016/j.vaccine.2024.04.045_b0505 Falay (10.1016/j.vaccine.2024.04.045_b0280) 2016; 16 Andrews (10.1016/j.vaccine.2024.04.045_b0400) 2020; 71 10.1016/j.vaccine.2024.04.045_b0020 10.1016/j.vaccine.2024.04.045_b0660 Bebell (10.1016/j.vaccine.2024.04.045_b0360) 2014; 9 Santos (10.1016/j.vaccine.2024.04.045_b0690) 2011; 139 10.1016/j.vaccine.2024.04.045_b0260 Park (10.1016/j.vaccine.2024.04.045_b0030) 2019; 69 10.1016/j.vaccine.2024.04.045_b0655 10.1016/j.vaccine.2024.04.045_b0410 10.1016/j.vaccine.2024.04.045_b0650 Nyirenda (10.1016/j.vaccine.2024.04.045_b0175) 2018; 20 van Griensven (10.1016/j.vaccine.2024.04.045_b0430) 2020; 7 Church (10.1016/j.vaccine.2024.04.045_b0295) 2014; 12 De Micco (10.1016/j.vaccine.2024.04.045_b0695) 2022; 27 Ramani (10.1016/j.vaccine.2024.04.045_b0335) 2019; 69 Vojtek (10.1016/j.vaccine.2024.04.045_b0485) 2018; 50 Kirk (10.1016/j.vaccine.2024.04.045_b0325) 2015; 12 10.1016/j.vaccine.2024.04.045_b0495 Smith (10.1016/j.vaccine.2024.04.045_b9000) 2024; 14 10.1016/j.vaccine.2024.04.045_b0250 Rosanova (10.1016/j.vaccine.2024.04.045_b0330) 2002; 6 Tennant (10.1016/j.vaccine.2024.04.045_b0590) 2016; 34 MacLennan (10.1016/j.vaccine.2024.04.045_b0210) 2010; 328 Williams (10.1016/j.vaccine.2024.04.045_b0090) 2009; 374 10.1016/j.vaccine.2024.04.045_b0245 Crump (10.1016/j.vaccine.2024.04.045_b0455) 2015; 28 10.1016/j.vaccine.2024.04.045_b0365 Okoro (10.1016/j.vaccine.2024.04.045_b0040) 2012; 44 Boerth (10.1016/j.vaccine.2024.04.045_b0615) 2023; 11 Takem (10.1016/j.vaccine.2024.04.045_b0450) 2014; 13 Nyirenda (10.1016/j.vaccine.2024.04.045_b0160) 2014; 210 MacLennan (10.1016/j.vaccine.2024.04.045_b0165) 2014; 10 Appiah (10.1016/j.vaccine.2024.04.045_b0290) 2021; 105 Gilchrist (10.1016/j.vaccine.2024.04.045_b0025) 2019; 8 Gilchrist (10.1016/j.vaccine.2024.04.045_b0200) 2015; 15 Gordon (10.1016/j.vaccine.2024.04.045_b0270) 2008; 46 10.1016/j.vaccine.2024.04.045_b0680 Kim (10.1016/j.vaccine.2024.04.045_b9005) 2024; 14 Stockdale (10.1016/j.vaccine.2024.04.045_b0195) 2019; 3 10.1016/j.vaccine.2024.04.045_b9010 10.1016/j.vaccine.2024.04.045_b0315 Walsh (10.1016/j.vaccine.2024.04.045_b0285) 2000; 19 10.1016/j.vaccine.2024.04.045_b0555 10.1016/j.vaccine.2024.04.045_b0675 Kankwatira (10.1016/j.vaccine.2024.04.045_b0205) 2004; 34 Crump (10.1016/j.vaccine.2024.04.045_b0380) 2015; 61 Hausdorff (10.1016/j.vaccine.2024.04.045_b9020) 2024; 12 de Alwis (10.1016/j.vaccine.2024.04.045_b0190) 2019; 219 Jacobs (10.1016/j.vaccine.2024.04.045_b0350) 2019; 6 Goh (10.1016/j.vaccine.2024.04.045_b0530) 2016; 10 Kingsley (10.1016/j.vaccine.2024.04.045_b0035) 2009; 19 Watson (10.1016/j.vaccine.2024.04.045_b0390) 2015; 33 10.1016/j.vaccine.2024.04.045_b0670 10.1016/j.vaccine.2024.04.045_b0550 Schloesser (10.1016/j.vaccine.2024.04.045_b0150) 2004; 36 Baker (10.1016/j.vaccine.2024.04.045_b0010) 2016; 62 Boyd (10.1016/j.vaccine.2024.04.045_b0525) 2014; 21 10.1016/j.vaccine.2024.04.045_b0305 10.1016/j.vaccine.2024.04.045_b0665 10.1016/j.vaccine.2024.04.045_b0300 Hutubessy (10.1016/j.vaccine.2024.04.045_b0490) 2023; 21 10.1016/j.vaccine.2024.04.045_b0540 Ramachandran (10.1016/j.vaccine.2024.04.045_b0545) 2016; 23 Baliban (10.1016/j.vaccine.2024.04.045_b0600) 2020; 71 Tack (10.1016/j.vaccine.2024.04.045_b0225) 2020; 14 Galen (10.1016/j.vaccine.2024.04.045_b0595) 2016; 7 |
| References_xml | – reference: World Health Organization. WHO meeting report: Expert consultation on scope of non-typhoidal – reference: Daily J. Fever diagnostic technology landscape. 1st ed. Geneva: World Health Organization; 2018. – reference: [accessed 31 December 2021]. – volume: 27 start-page: 140 year: 2021 end-page: 149 ident: b0255 article-title: Estimate of burden and direct healthcare cost of infectious waterborne disease in the United States publication-title: Emerg Infect Dis – volume: 9 start-page: 11245 year: 2019 ident: b0425 article-title: Modeling and cost benefit analysis to guide deployment of POC diagnostics for non-typhoidal publication-title: Sci Rep – reference: infections in infants and young children in sub-Saharan Africa. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx – volume: 15 start-page: 32 year: 2016 ident: b0415 article-title: What proportion of publication-title: Ann Clin Microbiol Antimicrob – volume: 22 start-page: 918 year: 2023 end-page: 920 ident: b0640 article-title: The iNTS-GMMA vaccine: a promising step in non-typhoidal publication-title: Expert Rev Vaccines – volume: 21 start-page: 529 year: 2021 ident: b0055 article-title: Geographical distribution of risk factors for invasive non-typhoidal publication-title: BMC Infect Dis – volume: 22 start-page: 692 year: 2022 end-page: 705 ident: b0125 article-title: Complications and mortality of non-typhoidal publication-title: Lancet Infect Dis – reference: vaccines pipeline: opportunities and challenges. In: Abstract presented at: 12th International Conference on Typhoid & Other Invasive Salmonelloses; Virtual; 6–8 December 2021. – volume: 7 year: 2013 ident: b0060 article-title: Invasive non-typhoidal publication-title: PLoS Negl Trop Dis – volume: 12 year: 2017 ident: b0535 article-title: Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout publication-title: PLoS One – reference: Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. doi:10.15620/cdc:82532. – reference: Smith C, Smith E, Chiu C, Hinton J, Perez Sepulveda B, Gordon M, et al. The Challenge Non-Typhoidal – reference: World Health Organization. Assessing the programmatic suitability of vaccine candidates for WHO prequalification. WHO/IVB/12.10. 2012. – volume: 8 year: 2019 ident: b0025 article-title: Invasive nontyphoidal publication-title: EcoSal Plus – volume: 23 start-page: 520 year: 2016 end-page: 523 ident: b0545 article-title: Opsonophagocytic assay to evaluate immunogenicity of nontyphoidal publication-title: Clin Vaccine Immunol – reference: vaccine against AMR; 2020. – volume: 16 start-page: 1633 year: 2002 end-page: 1641 ident: b0080 article-title: Non-typhoidal publication-title: AIDS – reference: (NTS) and broadly protective – reference: Lu Y, Roy E, Zhang F, Hirsch A, MacLennan C, Malley R. MAPS vaccine against – volume: 12 year: 2015 ident: b0325 article-title: World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis publication-title: PLoS Med – volume: 10 year: 2016 ident: b0530 article-title: Bactericidal immunity to publication-title: PLoS Negl Trop Dis – reference: disease in sub-Saharan Africa. In: Abstract presented at: Vaccines Against – volume: 19 start-page: 312 year: 2000 end-page: 318 ident: b0285 article-title: Bacteremia in febrile Malawian children: clinical and microbiologic features publication-title: Pediatr Infect Dis J – volume: 71 start-page: S248 year: 2020 end-page: S256 ident: b0400 article-title: Healthcare utilization patterns for acute febrile illness in Bangladesh, Nepal, and Pakistan: results from the Surveillance for Enteric Fever in Asia Project publication-title: Clin Infect Dis – volume: 9 start-page: 347 year: 2014 end-page: 358 ident: b0360 article-title: Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? publication-title: Glob Heart – volume: 7 year: 2016 ident: b0595 article-title: Live attenuated human publication-title: EcoSal Plus – volume: 25 start-page: 230 year: 2006 end-page: 236 ident: b0085 article-title: bacteremia in Kenyan children publication-title: Pediatr Infect Dis J – reference: Hausdorff WP, Scheele S. If we build it, will they come? Assessing the full public health value of enteric vaccines. Abstract presented at: Vaccines Against – volume: 374 start-page: 1364 year: 2009 end-page: 1370 ident: b0090 article-title: Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study publication-title: Lancet – volume: 328 start-page: 508 year: 2010 end-page: 512 ident: b0210 article-title: Dysregulated humoral immunity to nontyphoidal publication-title: Science – reference: HIC-Vac. HIC-Vac annual meeting: 18-19 November 2021. [report] – reference: World Health Organization: Control and Response Strategies, Surveillance, Prevention and Control (SPC) Team. Global research agenda for antimicrobial resistance in human health: policy brief. World Health Organization; 2023. – volume: 14 year: 2020 ident: b0475 article-title: Response of extensively drug resistant publication-title: PLoS Negl Trop Dis – reference: Wellcome. Live attenuated non-transmissible – volume: 34 start-page: 198 year: 2004 end-page: 200 ident: b0205 article-title: Non-typhoidal publication-title: Trop Doct – volume: 14 year: 2024 ident: b9005 article-title: Examining geospatial and temporal distribution of invasive non-typhoidal Salmonella disease occurrence in sub-Saharan Africa: a systematic review and modelling study publication-title: BMJ Open – reference: (CHANTS) Consortium: Development of a non-typhoidal – reference: Levine MM, Chen WH, Barnes R, Sikorski M, Tennant S, Simon R, et al. Phase 1 trial of a trivalent – reference: conjugate vaccine to prevent invasive – volume: 83 start-page: 523 year: 2021 end-page: 532 ident: b0130 article-title: Incidence of non-typhoidal publication-title: J Infect – volume: 69 start-page: S422 year: 2019 end-page: S434 ident: b0030 article-title: The Severe Typhoid Fever in Africa Program: study design and methodology to assess disease severity, host immunity, and carriage associated with invasive salmonellosis publication-title: Clin Infect Dis – reference: An S. Development of iNTS conjugate and preclinical study for a novel trivalent iNTS/typhoid vaccine. In: Abstract presented at: 13th International Conference on Typhoid & Other Invasive Salmonelloses; Kigali, Rwanda; 5–7 December 2023. – reference: Kariuki SM. Nontyphoidal – volume: 16 start-page: 271 year: 2016 ident: b0280 article-title: Microbiological, clinical and molecular findings of non-typhoidal publication-title: BMC Infect Dis – reference: invasive disease: challenges and solutions? In: Roundtable session at: 12th international conference on typhoid & other invasive salmonelloses; Virtual; 6–8 December 2021. – volume: 28 start-page: 901 year: 2015 end-page: 937 ident: b0455 article-title: Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive publication-title: Clin Microbiol Rev – volume: 50 start-page: 193 year: 2018 end-page: 208 ident: b0485 article-title: Maternal immunization: where are we now and how to move forward? publication-title: Ann Med – reference: conjugate vaccine to prevent invasive non-typhoidal – volume: 9 year: 2015 ident: b0100 article-title: Modelling the contributions of malaria, HIV, malnutrition and rainfall to the decline in paediatric invasive non-typhoidal publication-title: PLoS Negl Trop Dis – volume: 6 year: 2019 ident: b0350 article-title: Diagnostic bacteriology in district hospitals in sub-Saharan Africa: at the forefront of the containment of antimicrobial resistance publication-title: Front Med – reference: [accessed 9 May 2022]. – volume: 67 start-page: 1824 year: 2018 end-page: 1830 ident: b0480 article-title: Determining the best immunization strategy for protecting African children against invasive publication-title: Clin Infect Dis – volume: 13 year: 2023 ident: b0645 article-title: Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort publication-title: BMJ Open – volume: 210 start-page: 56 year: 2014 end-page: 64 ident: b0160 article-title: Sequential acquisition of T cells and antibodies to nontyphoidal publication-title: J Infect Dis – volume: 221 start-page: 1098 year: 2020 end-page: 1106 ident: b0440 article-title: Cytokine profile distinguishes children with publication-title: J Infect Dis – reference: invasive disease: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019;19(12):1312–24. doi:10.1016/S1473-3099(19)30418-9. – volume: 14 year: 2020 ident: b0225 article-title: Non-typhoidal publication-title: PLoS Negl Trop Dis – reference: and ETEC (VASE) Virtual Symposium; 30 September 2021. – reference: vaccines. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx – volume: 16 start-page: 2056 year: 2020 end-page: 2071 ident: b0110 article-title: Pathogenic signature of invasive non-typhoidal publication-title: Hum Vaccin Immunother – reference: and ETEC (VASE) Virtual Symposium; 28 September 2021. – reference: Institute for Health Metrics and Evaluation, University of Washington. GBD Results Tool | GHDx. Global Health Data Exchange; 2021. – volume: 105 start-page: 37 year: 2021 end-page: 46 ident: b0290 article-title: bloodstream infections in hospitalized children with acute febrile illness–Uganda, 2016–2019 publication-title: Am J Trop Med Hyg – volume: 71 start-page: S151 year: 2020 end-page: S154 ident: b0600 article-title: Overview of the nontyphoidal and paratyphoidal publication-title: Clin Infect Dis – reference: WHO Guidelines for malaria. Geneva: World Health Organization; 2021 February 16. WHO/UCN/GMP/2021.01. – reference: MacLennan CA. The background, role and approach for development of a controlled human infection model for nontyphoidal – volume: 20 start-page: 41 year: 2000 end-page: 44 ident: b0145 article-title: Salmonella meningitis in children in Blantyre, Malawi, 1996–1999 publication-title: Ann Trop Paediatr – reference: GBD 2017 Non-Typhoidal – volume: 139 start-page: 742 year: 2011 end-page: 753 ident: b0690 article-title: Typhimurium and publication-title: Epidemiol Infect – volume: 387 start-page: 121 year: 2013 end-page: 129 ident: b0520 article-title: Invasive African nontyphoidal publication-title: J Immunol Methods – volume: 21 start-page: 229 year: 2023 ident: b0490 article-title: The Full Value of Vaccine Assessments (FVVA): a framework to assess and communicate the value of vaccines for investment and introduction decision making publication-title: BMC Med – reference: WHO Country Office for India and Department of Biotechnology, Government of India. Indian priority pathogen list; 2021. – volume: 68 start-page: S10 year: 2019 end-page: S15 ident: b0685 article-title: Multidrug-resistant nontyphoidal publication-title: Clin Infect Dis – volume: 36 start-page: 773 year: 2004 end-page: 774 ident: b0150 article-title: Fatal transplacental infection with non-typhoidal publication-title: Scand J Infect Dis – volume: 68 start-page: S96 year: 2019 end-page: S ident: b0395 article-title: Predicting the impact of typhoid conjugate vaccines on antimicrobial resistance publication-title: Clin Infect Dis – volume: 33 start-page: C8 year: 2015 end-page: C ident: b0420 article-title: Diagnostics for invasive publication-title: Vaccine – volume: 14 year: 2024 Jan 10 ident: b9000 article-title: Protocol for the challenge non-typhoidal Salmonella (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK publication-title: BMJ Open – volume: 20 start-page: 619 year: 2020 end-page: 636 ident: b0435 article-title: Companion and complementary diagnostics for infectious diseases publication-title: Expert Rev Mol Diagn – reference: Invasive Disease Collaborators. The global burden of non-typhoidal – reference: World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) 2015. – reference: World Health Organization. Requests to initiate new WHO reference material projects for vaccines and related substances. WHO/BS/2015.2272. Geneva; 2015. – reference: PMID. – reference: Wellcome. Full value of vaccines assessment for invasive non-typhoidal – reference: CARB-X. GSK iNTS-TCV vaccine: prevention of iNTS and typhoid fever. CARB-X Portfolio Product Developers. 2020. – volume: 58 start-page: 638 year: 2014 end-page: 647 ident: b0095 article-title: Invasive publication-title: Clin Infect Dis – volume: 61 start-page: S235 year: 2015 end-page: S240 ident: b0380 article-title: A perspective on invasive publication-title: Clin Infect Dis – volume: 33 start-page: C55 year: 2015 end-page: C61 ident: b0385 article-title: Typhoid fever vaccination strategies publication-title: Vaccine – reference: Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America; 2019. – volume: 11 year: 2023 ident: b0615 article-title: Induction of broad immunity against invasive publication-title: Vaccines – volume: 5 start-page: e310 year: 2017 end-page: e323 ident: b0015 article-title: Incidence of invasive publication-title: Lancet Glob Health – volume: 13 start-page: 400 year: 2014 ident: b0450 article-title: The association between malaria and non-typhoid publication-title: Malar J – reference: Wellcome. Developing a conjugated Vaccine to prevent invasive non-typhoidal – volume: 19 start-page: 2279 year: 2009 end-page: 2287 ident: b0035 article-title: Epidemic multiple drug resistant publication-title: Genome Res – reference: Levine M, Chen W, Barnes R, Sikorski M, Tennant S, Simon R, et al. Phase 1 trial of a trivalent – volume: 118 start-page: 1553 year: 2008 end-page: 1562 ident: b0180 article-title: The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of publication-title: J Clin Invest – volume: 219 start-page: 295 year: 2019 end-page: 304 ident: b0190 article-title: The role of maternally acquired antibody in providing protective immunity against nontyphoidal publication-title: J Infect Dis – volume: 73 start-page: e1570 year: 2021 end-page: e1578 ident: b0075 article-title: Investigating the meat pathway as a source of human nontyphoidal publication-title: Clin Infect Dis – reference: . In: Ahmed R, Akira S, Casadevall A, Galan JE, Garcia-Sastre A, Rappuoli R, et al, editors. Current topics in microbiology and immunology. Berlin, Heidelberg: Springer; 2021. doi:10.1007/82_2021_246. – reference: Ramasamy M, Ramasamy M, Hanumunthadu BK, Oxford Vaccine Group. – volume: 44 start-page: 1215 year: 2012 end-page: 1221 ident: b0040 article-title: Intracontinental spread of human invasive publication-title: Nat Genet – reference: World Health Organization. Framework on value of non-typhoidal – reference: [accessed 31 December 2021]. – reference: infections. Wellcome Trust Innov Awards - Grants Funded 2021. – volume: 152 start-page: e4 year: 2023 ident: b0220 article-title: Vacc-iNTS Consortium Collaborators. Prevalence and distribution of non-typhoidal publication-title: Epidemiol Infect – volume: 21 start-page: 941 year: 2015 end-page: 949 ident: b0005 article-title: Global burden of invasive nontyphoidal publication-title: Emerg Infect Dis – reference: (iNTS) — Level 3 cause; 2019. – reference: infections and typhoid fever in sub-Saharan Africa. In: Abstract presented at: 12th international conference on typhoid & other invasive salmonelloses; Virtual; 6–8 December 2021. – reference: Bentsi-Enchill, A. Evidence considerations for vaccine policy (ECVP)* development: Test case for a bivalent typhoid/paratyphoid A vaccine. Abstract presented at: Vaccines Against – reference: PEDVAC-iNTS: Pediatric phase I/II age de-escalation dose-finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa. In: New drugs and vaccines for priority pathogens in antimicrobial resistance – 2019. – volume: 14 year: 2020 ident: b0070 article-title: High relatedness of invasive multi-drug resistant non-typhoidal publication-title: PLoS Negl Trop Dis – reference: disease in sub-Saharan Africa. In: Abstract presented at: 12th International Conference on Typhoid & Other Invasive Salmonelloses; Virtual; 6–8 December 2021. – volume: 69 start-page: S459 year: 2019 end-page: S465 ident: b0335 article-title: A multicenter cost-of-illness and long-term socioeconomic follow-up study in the Severe Typhoid Fever in Africa Program: study protocol publication-title: Clin Infect Dis – volume: 46 start-page: 963 year: 2008 end-page: 969 ident: b0270 article-title: Epidemics of invasive publication-title: Clin Infect Dis – reference: Canals R. Development of GMMA-based vaccines against iNTS: current status. In: Abstract presented at: 13th International Conference on Typhoid & Other Invasive Salmonelloses; Kigali, Rwanda; 5–7 December 2023. – reference: vaccines; Virtual; 22 and 24 September 2021. – reference: (iNTS) vaccines; 2022. – volume: 24 start-page: e00057 year: 2017 end-page: e117 ident: b0215 article-title: Loss of humoral and cellular immunity to invasive nontyphoidal publication-title: Clin Vaccine Immunol CVI – volume: 33 start-page: C42 year: 2015 end-page: C54 ident: b0390 article-title: A review of typhoid fever transmission dynamic models and economic evaluations of vaccination publication-title: Vaccine – volume: 399 start-page: 629 year: 2022 end-page: 655 ident: b0265 article-title: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis publication-title: Lancet – volume: 15 start-page: 1545 year: 2016 end-page: 1555 ident: b0170 article-title: Immunology, epidemiology and mathematical modelling towards a better understanding of invasive non-typhoidal publication-title: Expert Rev Vaccines – reference: invasive disease: challenges and solutions? Roundtable session at: 12th International Conference on Typhoid & Other Invasive Salmonelloses; Virtual; 6–8 December 2021. – volume: 61 start-page: S317 year: 2015 end-page: S324 ident: b0050 article-title: Epidemiology and genomics of invasive nontyphoidal publication-title: Clin Infect Dis – volume: 62 start-page: S1 year: 2016 end-page: S3 ident: b0010 article-title: What have we learned from the Typhoid Fever Surveillance in Africa Program? publication-title: Clin Infect Dis – reference: Wellcome. Modified Outer Membrane Vesicles (mOMV) as safe, effective, low cost, multivalent vaccines against typhoid and paratyphoid fever and invasive non-typhoidal – reference: Wellcome Trust, Boston Consulting Group. Vaccines to tackle drug resistant infections: an evaluation of R&D opportunities; 2018. – reference: H2020. Vacc-iNTS: Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa. CORDIS - EU research projects under Horizon 2020 (2014–2020). – reference: Blumentrath CG, Müller G, Teichmann D, Tiesmeier J, Petridou J. Relapse of typhoid fever following delayed response to meropenem: a case report and review of previously published cases indicating limited clinical efficacy of meropenem for the treatment of typhoid fever. Ger Med Sci 2019;17:Doc01. doi:10.3205/000267. – volume: 10 start-page: 1478 year: 2014 end-page: 1493 ident: b0165 article-title: Vaccines against invasive publication-title: Hum Vaccin Immunother – reference: serovars Typhimurium and Enteritidis. In: Abstract presented at: 12th International Conference on Typhoid & Other Invasive Salmonelloses; Virtual; 6-8 December 2021. – volume: 7 year: 2020 ident: b0430 article-title: Point-of-care biomarkers to guide antibiotic prescription for acute febrile illness in sub-Saharan Africa: promises and caveats publication-title: Open Forum Infect Dis – volume: 18 start-page: 318 year: 2018 end-page: 327 ident: b0240 article-title: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis publication-title: Lancet Infect Dis – reference: MacLennan, C. Typhoid and combination – reference: [accessed 30 December 2021]. – volume: 20 start-page: 589 year: 2018 end-page: 598 ident: b0175 article-title: Immunological bases of increased susceptibility to invasive nontyphoidal publication-title: Microbes Infect – volume: 27 start-page: 391 year: 2022 end-page: 409 ident: b0695 article-title: The costs of introducing a vaccine in sub-Saharan Africa: a systematic review of the literature publication-title: Int J Health Gov – reference: (iNTS) vaccines; Virtual; 29 November–1 December 2021. – volume: 61 start-page: S272 year: 2015 end-page: S282 ident: b0155 article-title: Clinical and microbiological features of publication-title: Clin Infect Dis – volume: 12 start-page: 31 year: 2014 ident: b0295 article-title: Invasive bacterial co-infection in African children with publication-title: BMC Med – volume: 34 start-page: 2907 year: 2016 end-page: 2910 ident: b0590 article-title: Nontyphoidal publication-title: Vaccine – volume: 11 year: 2017 ident: b0135 article-title: Presentation of life-threatening invasive nontyphoidal publication-title: PLoS Negl Trop Dis – volume: 340 year: 2010 ident: b0405 article-title: WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense publication-title: BMJ – volume: 13 year: 2019 ident: b0045 article-title: Emergence of phylogenetically diverse and fluoroquinolone resistant publication-title: PLoS Negl Trop Dis – volume: 11 start-page: 21617 year: 2021 ident: b0140 article-title: Direct association between rainfall and non-typhoidal publication-title: Sci Rep – reference: Heyderman RS, Crump JA, on behalf of the conference attendees. Invasive Salmonella in Africa consensus meeting 2014, Blantyre, Malawi. Emerg Infect Dis. 2015 Nov; 21(11): e150624. – volume: 18 start-page: 212 year: 2020 ident: b0275 article-title: Invasive non-typhoidal publication-title: BMC Med – reference: World Health Organization. WHO meeting report: expert consultation on invasive non-typhoidal – volume: 61 start-page: S266 year: 2015 end-page: S271 ident: b0560 article-title: Control of invasive publication-title: Clin Infect Dis – volume: 13 year: 2019 ident: b0065 article-title: Supporting evidence for a human reservoir of invasive non-Typhoidal publication-title: PLoS Negl Trop Dis – reference: O’Neill J. Tackling drug-resistant infections globally: final report and recommendation; 2016. – volume: 20 start-page: 1957 year: 2014 end-page: 1959 ident: b0460 article-title: Drug resistance in publication-title: Malawi Emerg Infect Dis – reference: vaccine study in Oxford; 2022. doi:10.1186/ISRCTN51750695. – reference: Institute for Health Metrics and Evaluation. Invasive non-typhoidal – volume: 15 start-page: 452 year: 2015 end-page: 463 ident: b0200 article-title: Genetic susceptibility to invasive publication-title: Nat Rev Immunol – volume: 9 start-page: 20310 year: 2019 ident: b0310 article-title: Distinct climate influences on the risk of typhoid compared to invasive non-typhoid publication-title: Sci Rep – reference: World Health Organization. PDVAC (virtual) meeting on invasive non-typhoidal – volume: 12 start-page: e1059 year: 2024 end-page: e1067 ident: b9020 article-title: Facilitating the development of urgently required combination vaccines publication-title: Lancet Glob Health – volume: 107 start-page: 3070 year: 2010 end-page: 3075 ident: b0185 article-title: Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal publication-title: Proc Natl Acad Sci – volume: 11 year: 2017 ident: b0370 article-title: Modeling the potential for vaccination to diminish the burden of invasive non-typhoidal publication-title: PLoS Negl Trop Dis – volume: 33 start-page: 2079 year: 2015 end-page: 2085 ident: b0375 article-title: Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda publication-title: Vaccine – reference: [accessed 27 November 2023]. – volume: 61 start-page: S310 year: 2015 end-page: S316 ident: b0465 article-title: Emergence of community-acquired, multidrug-resistant invasive nontyphoidal publication-title: Clin Infect Dis – volume: 21 start-page: 712 year: 2014 end-page: 721 ident: b0525 article-title: Serum bactericidal assays to evaluate typhoidal and nontyphoidal publication-title: Clin Vaccine Immunol – reference: World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring; 2014. – volume: 3 year: 2019 ident: b0195 article-title: Cross-sectional study of IgG antibody levels to invasive nontyphoidal publication-title: Gates Open Res – reference: Wellcome. Process development and preclinical toxicity study for trivalent Typhi/iNTS vaccine. Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021.xlsx – volume: 61 start-page: S363 year: 2015 end-page: S371 ident: b0105 article-title: Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014 publication-title: Clin Infect Dis – reference: Kalonji LM, Phoba M-F. Kariuki SM. Nontyphoidal – volume: 6 start-page: 187 year: 2002 end-page: 190 ident: b0330 article-title: Risk factors for mortality caused by nontyphoidal publication-title: Int J Infect Dis – reference: controlled human infection model: report from a consultation group workshop, 05 July 2022, London, UK. Wellcome Open Res 2023;8:111. doi:10.12688/wellcomeopenres.19012.2. – reference: Wellcome Trust, Bill & Melinda Gates Foundation. Meeting report: non-typhoidal (NTS) CHIM workshop, 27 January 2021. – reference: Canals R, Cappelletti E, Necchi F, Vitali C, Micoli F, Martin L, et al. An effective, affordable and sustainable vaccine to tackle – reference: World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) Report: 2021. – ident: 10.1016/j.vaccine.2024.04.045_b0445 – ident: 10.1016/j.vaccine.2024.04.045_b0365 – ident: 10.1016/j.vaccine.2024.04.045_b9010 doi: 10.3201/eid2111.150624 – volume: 15 start-page: 1545 issue: 12 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0170 article-title: Immunology, epidemiology and mathematical modelling towards a better understanding of invasive non-typhoidal Salmonella disease and rational vaccination approaches publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2016.1189330 – volume: 221 start-page: 1098 issue: 7 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0440 article-title: Cytokine profile distinguishes children with Plasmodium falciparum malaria from those with bacterial blood stream infections publication-title: J Infect Dis doi: 10.1093/infdis/jiz587 – volume: 68 start-page: S96 issue: Suppl 2 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0395 article-title: Predicting the impact of typhoid conjugate vaccines on antimicrobial resistance publication-title: Clin Infect Dis doi: 10.1093/cid/ciy1108 – ident: 10.1016/j.vaccine.2024.04.045_b0605 – ident: 10.1016/j.vaccine.2024.04.045_b0345 – ident: 10.1016/j.vaccine.2024.04.045_b0540 – ident: 10.1016/j.vaccine.2024.04.045_b0620 – volume: 152 start-page: e4 year: 2023 ident: 10.1016/j.vaccine.2024.04.045_b0220 article-title: Vacc-iNTS Consortium Collaborators. Prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars isolated from normally sterile sites: a global systematic review publication-title: Epidemiol Infect doi: 10.1017/S0950268823001693 – volume: 13 issue: 6 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0045 article-title: Emergence of phylogenetically diverse and fluoroquinolone resistant Salmonella Enteritidis as a cause of invasive nontyphoidal Salmonella disease in Ghana publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0007485 – volume: 118 start-page: 1553 issue: 4 year: 2008 ident: 10.1016/j.vaccine.2024.04.045_b0180 article-title: The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children publication-title: J Clin Invest doi: 10.1172/JCI33998 – volume: 33 start-page: 2079 issue: 17 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0375 article-title: Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda publication-title: Vaccine doi: 10.1016/j.vaccine.2015.02.027 – volume: 50 start-page: 193 issue: 3 year: 2018 ident: 10.1016/j.vaccine.2024.04.045_b0485 article-title: Maternal immunization: where are we now and how to move forward? publication-title: Ann Med doi: 10.1080/07853890.2017.1421320 – volume: 14 issue: 4 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0225 article-title: Non-typhoidal Salmonella bloodstream infections in Kisantu, DR Congo: emergence of O5-negative Salmonella Typhimurium and extensive drug resistance publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0008121 – volume: 83 start-page: 523 issue: 5 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0130 article-title: Incidence of non-typhoidal Salmonella invasive disease: a systematic review and meta-analysis publication-title: J Infect doi: 10.1016/j.jinf.2021.06.029 – volume: 328 start-page: 508 issue: 5977 year: 2010 ident: 10.1016/j.vaccine.2024.04.045_b0210 article-title: Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults publication-title: Science doi: 10.1126/science.1180346 – volume: 15 start-page: 32 issue: 1 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0415 article-title: What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review publication-title: Ann Clin Microbiol Antimicrob doi: 10.1186/s12941-016-0147-z – volume: 33 start-page: C42 issue: Suppl 3 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0390 article-title: A review of typhoid fever transmission dynamic models and economic evaluations of vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2015.04.013 – ident: 10.1016/j.vaccine.2024.04.045_b0230 – volume: 6 start-page: 187 issue: 3 year: 2002 ident: 10.1016/j.vaccine.2024.04.045_b0330 article-title: Risk factors for mortality caused by nontyphoidal Salmonella sp. in children publication-title: Int J Infect Dis doi: 10.1016/S1201-9712(02)90109-8 – ident: 10.1016/j.vaccine.2024.04.045_b0660 – volume: 18 start-page: 318 issue: 3 year: 2018 ident: 10.1016/j.vaccine.2024.04.045_b0240 article-title: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30753-3 – volume: 5 start-page: e310 issue: 3 year: 2017 ident: 10.1016/j.vaccine.2024.04.045_b0015 article-title: Incidence of invasive Salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30022-0 – volume: 387 start-page: 121 issue: 1–2 year: 2013 ident: 10.1016/j.vaccine.2024.04.045_b0520 article-title: Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing publication-title: J Immunol Methods doi: 10.1016/j.jim.2012.10.005 – volume: 21 start-page: 712 issue: 5 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0525 article-title: Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00115-14 – ident: 10.1016/j.vaccine.2024.04.045_b0245 – ident: 10.1016/j.vaccine.2024.04.045_b0675 – volume: 44 start-page: 1215 issue: 11 year: 2012 ident: 10.1016/j.vaccine.2024.04.045_b0040 article-title: Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa publication-title: Nat Genet doi: 10.1038/ng.2423 – ident: 10.1016/j.vaccine.2024.04.045_b0115 – volume: 8 issue: 2 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0025 article-title: Invasive nontyphoidal Salmonella disease in Africa publication-title: EcoSal Plus doi: 10.1128/ecosalplus.esp-0007-2018 – volume: 16 start-page: 271 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0280 article-title: Microbiological, clinical and molecular findings of non-typhoidal Salmonella bloodstream infections associated with malaria, Oriental Province, Democratic Republic of the Congo publication-title: BMC Infect Dis doi: 10.1186/s12879-016-1604-1 – volume: 14 issue: 3 year: 2024 ident: 10.1016/j.vaccine.2024.04.045_b9005 article-title: Examining geospatial and temporal distribution of invasive non-typhoidal Salmonella disease occurrence in sub-Saharan Africa: a systematic review and modelling study publication-title: BMJ Open doi: 10.1136/bmjopen-2023-080501 – volume: 139 start-page: 742 issue: 5 year: 2011 ident: 10.1016/j.vaccine.2024.04.045_b0690 article-title: Salmonella Typhimurium and Salmonella Enteritidis in England: costs to patients, their families, and primary and community health services of the NHS publication-title: Epidemiol Infect doi: 10.1017/S0950268810001615 – volume: 107 start-page: 3070 issue: 7 year: 2010 ident: 10.1016/j.vaccine.2024.04.045_b0185 article-title: Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0910497107 – volume: 7 issue: 10 year: 2013 ident: 10.1016/j.vaccine.2024.04.045_b0060 article-title: Invasive non-typhoidal Salmonella typhimurium ST313 are not host-restricted and have an invasive phenotype in experimentally infected chickens publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0002487 – ident: 10.1016/j.vaccine.2024.04.045_b0305 – volume: 210 start-page: 56 issue: 1 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0160 article-title: Sequential acquisition of T cells and antibodies to nontyphoidal Salmonella in Malawian children publication-title: J Infect Dis doi: 10.1093/infdis/jiu045 – ident: 10.1016/j.vaccine.2024.04.045_b0340 – ident: 10.1016/j.vaccine.2024.04.045_b0665 – volume: 69 start-page: S422 issue: Suppl 6 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0030 article-title: The Severe Typhoid Fever in Africa Program: study design and methodology to assess disease severity, host immunity, and carriage associated with invasive salmonellosis publication-title: Clin Infect Dis doi: 10.1093/cid/ciz715 – ident: 10.1016/j.vaccine.2024.04.045_b0495 – volume: 10 issue: 4 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0530 article-title: Bactericidal immunity to Salmonella in Africans and mechanisms causing its failure in HIV infection publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0004604 – ident: 10.1016/j.vaccine.2024.04.045_b0235 – ident: 10.1016/j.vaccine.2024.04.045_b0510 – ident: 10.1016/j.vaccine.2024.04.045_b0670 – volume: 9 start-page: 11245 issue: 1 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0425 article-title: Modeling and cost benefit analysis to guide deployment of POC diagnostics for non-typhoidal Salmonella infections with antimicrobial resistance publication-title: Sci Rep doi: 10.1038/s41598-019-47359-2 – volume: 13 issue: 11 year: 2023 ident: 10.1016/j.vaccine.2024.04.045_b0645 article-title: Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort publication-title: BMJ Open doi: 10.1136/bmjopen-2023-072938 – ident: 10.1016/j.vaccine.2024.04.045_b0320 – volume: 11 start-page: 21617 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0140 article-title: Direct association between rainfall and non-typhoidal Salmonella bloodstream infections in hospital-admitted children in the Democratic Republic of Congo publication-title: Sci Rep doi: 10.1038/s41598-021-01030-x – volume: 19 start-page: 312 issue: 4 year: 2000 ident: 10.1016/j.vaccine.2024.04.045_b0285 article-title: Bacteremia in febrile Malawian children: clinical and microbiologic features publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200004000-00010 – ident: 10.1016/j.vaccine.2024.04.045_b0410 – ident: 10.1016/j.vaccine.2024.04.045_b0650 doi: 10.1186/ISRCTN51750695 – ident: 10.1016/j.vaccine.2024.04.045_b0580 – volume: 25 start-page: 230 issue: 3 year: 2006 ident: 10.1016/j.vaccine.2024.04.045_b0085 article-title: Salmonella bacteremia in Kenyan children publication-title: Pediatr Infect Dis J doi: 10.1097/01.inf.0000202066.02212.ff – volume: 10 start-page: 1478 issue: 6 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0165 article-title: Vaccines against invasive Salmonella disease: current status and future directions publication-title: Hum Vaccin Immunother doi: 10.4161/hv.29054 – volume: 11 issue: 11 year: 2023 ident: 10.1016/j.vaccine.2024.04.045_b0615 article-title: Induction of broad immunity against invasive Salmonella disease by a quadrivalent combination Salmonella MAPS vaccine targeting Salmonella enterica serovars Typhimurium, Enteritidis, Typhi, and Paratyphi A publication-title: Vaccines doi: 10.3390/vaccines11111671 – volume: 73 start-page: e1570 issue: 7 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0075 article-title: Investigating the meat pathway as a source of human nontyphoidal Salmonella bloodstream infections and diarrhea in East Africa publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1153 – volume: 22 start-page: 692 issue: 5 year: 2022 ident: 10.1016/j.vaccine.2024.04.045_b0125 article-title: Complications and mortality of non-typhoidal Salmonella invasive disease: a global systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00615-0 – volume: 20 start-page: 41 issue: 1 year: 2000 ident: 10.1016/j.vaccine.2024.04.045_b0145 article-title: Salmonella meningitis in children in Blantyre, Malawi, 1996–1999 publication-title: Ann Trop Paediatr doi: 10.1080/02724930092057 – ident: 10.1016/j.vaccine.2024.04.045_b0625 – ident: 10.1016/j.vaccine.2024.04.045_b0515 – volume: 19 start-page: 2279 issue: 12 year: 2009 ident: 10.1016/j.vaccine.2024.04.045_b0035 article-title: Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype publication-title: Genome Res doi: 10.1101/gr.091017.109 – ident: 10.1016/j.vaccine.2024.04.045_b0300 – ident: 10.1016/j.vaccine.2024.04.045_b0585 – volume: 27 start-page: 140 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0255 article-title: Estimate of burden and direct healthcare cost of infectious waterborne disease in the United States publication-title: Emerg Infect Dis doi: 10.3201/eid2701.190676 – volume: 20 start-page: 589 issue: 9–10 year: 2018 ident: 10.1016/j.vaccine.2024.04.045_b0175 article-title: Immunological bases of increased susceptibility to invasive nontyphoidal Salmonella infection in children with malaria and anaemia publication-title: Microbes Infect doi: 10.1016/j.micinf.2017.11.014 – volume: 27 start-page: 391 issue: 4 year: 2022 ident: 10.1016/j.vaccine.2024.04.045_b0695 article-title: The costs of introducing a vaccine in sub-Saharan Africa: a systematic review of the literature publication-title: Int J Health Gov – ident: 10.1016/j.vaccine.2024.04.045_b0260 – ident: 10.1016/j.vaccine.2024.04.045_b0120 – volume: 16 start-page: 1633 issue: 12 year: 2002 ident: 10.1016/j.vaccine.2024.04.045_b0080 article-title: Non-typhoidal Salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence publication-title: AIDS doi: 10.1097/00002030-200208160-00009 – ident: 10.1016/j.vaccine.2024.04.045_b0550 – volume: 46 start-page: 963 issue: 7 year: 2008 ident: 10.1016/j.vaccine.2024.04.045_b0270 article-title: Epidemics of invasive Salmonella enterica serovar Enteritidis and S. enterica serovar Typhimurium infection associated with multidrug resistance among adults and children in Malawi publication-title: Clin Infect Dis doi: 10.1086/529146 – ident: 10.1016/j.vaccine.2024.04.045_b0470 – volume: 12 start-page: 31 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0295 article-title: Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review publication-title: BMC Med doi: 10.1186/1741-7015-12-31 – volume: 9 start-page: 347 issue: 3 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0360 article-title: Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? publication-title: Glob Heart doi: 10.1016/j.gheart.2014.08.009 – volume: 28 start-page: 901 issue: 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0455 article-title: Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00002-15 – ident: 10.1016/j.vaccine.2024.04.045_b0250 doi: 10.15620/cdc:82532 – volume: 68 start-page: S10 issue: Suppl 1 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0685 article-title: Multidrug-resistant nontyphoidal Salmonella hotspots as targets for vaccine use in management of infections in endemic settings publication-title: Clin Infect Dis doi: 10.1093/cid/ciy898 – volume: 20 start-page: 1957 issue: 11 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0460 article-title: Drug resistance in Salmonella enterica ser. Typhimurium bloodstream infection publication-title: Malawi Emerg Infect Dis doi: 10.3201/eid2011.141175 – volume: 21 start-page: 941 issue: 6 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0005 article-title: Global burden of invasive nontyphoidal Salmonella disease, 2010 publication-title: Emerg Infect Dis doi: 10.3201/eid2106.140999 – ident: 10.1016/j.vaccine.2024.04.045_b0355 – ident: 10.1016/j.vaccine.2024.04.045_b0630 – volume: 14 issue: 10 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0475 article-title: Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0008682 – volume: 11 issue: 12 year: 2017 ident: 10.1016/j.vaccine.2024.04.045_b0135 article-title: Presentation of life-threatening invasive nontyphoidal Salmonella disease in Malawian children: a prospective observational study publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0006027 – volume: 71 start-page: S151 issue: Suppl 2 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0600 article-title: Overview of the nontyphoidal and paratyphoidal Salmonella vaccine pipeline: current status and future prospects publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa514 – volume: 33 start-page: C8 issue: Suppl 3 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0420 article-title: Diagnostics for invasive Salmonella infections: current challenges and future directions publication-title: Vaccine doi: 10.1016/j.vaccine.2015.02.030 – volume: 34 start-page: 198 issue: 4 year: 2004 ident: 10.1016/j.vaccine.2024.04.045_b0205 article-title: Non-typhoidal Salmonella bacteraemia - an under-recognized feature of AIDS in African adults publication-title: Trop Doct doi: 10.1177/004947550403400404 – volume: 33 start-page: C55 issue: Suppl 3 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0385 article-title: Typhoid fever vaccination strategies publication-title: Vaccine doi: 10.1016/j.vaccine.2015.04.028 – volume: 12 start-page: e1059 issue: 6 year: 2024 ident: 10.1016/j.vaccine.2024.04.045_b9020 article-title: Facilitating the development of urgently required combination vaccines publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(24)00092-5 – volume: 62 start-page: S1 issue: Suppl 1 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0010 article-title: What have we learned from the Typhoid Fever Surveillance in Africa Program? publication-title: Clin Infect Dis doi: 10.1093/cid/civ675 – volume: 105 start-page: 37 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0290 article-title: Salmonella bloodstream infections in hospitalized children with acute febrile illness–Uganda, 2016–2019 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.20-1453 – volume: 7 issue: 8 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0430 article-title: Point-of-care biomarkers to guide antibiotic prescription for acute febrile illness in sub-Saharan Africa: promises and caveats publication-title: Open Forum Infect Dis – ident: 10.1016/j.vaccine.2024.04.045_b0020 doi: 10.1016/S1473-3099(19)30418-9 – volume: 58 start-page: 638 issue: 5 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0095 article-title: Invasive Salmonella infections in areas of high and low malaria transmission intensity in Tanzania publication-title: Clin Infect Dis doi: 10.1093/cid/cit798 – volume: 67 start-page: 1824 issue: 12 year: 2018 ident: 10.1016/j.vaccine.2024.04.045_b0480 article-title: Determining the best immunization strategy for protecting African children against invasive Salmonella disease publication-title: Clin Infect Dis doi: 10.1093/cid/ciy386 – volume: 12 issue: 12 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0325 article-title: World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis publication-title: PLoS Med – volume: 21 start-page: 229 issue: 1 year: 2023 ident: 10.1016/j.vaccine.2024.04.045_b0490 article-title: The Full Value of Vaccine Assessments (FVVA): a framework to assess and communicate the value of vaccines for investment and introduction decision making publication-title: BMC Med doi: 10.1186/s12916-023-02929-0 – volume: 340 year: 2010 ident: 10.1016/j.vaccine.2024.04.045_b0405 article-title: WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense Plasmodium falciparum transmission: prospective study publication-title: BMJ doi: 10.1136/bmj.c1350 – volume: 14 issue: 8 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0070 article-title: High relatedness of invasive multi-drug resistant non-typhoidal Salmonella genotypes among patients and asymptomatic carriers in endemic informal settlements in Kenya publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0008440 – volume: 7 issue: 1 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0595 article-title: Live attenuated human Salmonella vaccine candidates: tracking the pathogen in natural infection and stimulation of host immunity publication-title: EcoSal Plus doi: 10.1128/ecosalplus.esp-0010-2016 – volume: 61 start-page: S317 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0050 article-title: Epidemiology and genomics of invasive nontyphoidal Salmonella infections in Kenya publication-title: Clin Infect Dis doi: 10.1093/cid/civ711 – ident: 10.1016/j.vaccine.2024.04.045_b0575 – volume: 16 start-page: 2056 issue: 9 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0110 article-title: Pathogenic signature of invasive non-typhoidal Salmonella in Africa: implications for vaccine development publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2020.1785791 – volume: 12 issue: 2 year: 2017 ident: 10.1016/j.vaccine.2024.04.045_b0535 article-title: Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout publication-title: PLoS One doi: 10.1371/journal.pone.0172163 – volume: 36 start-page: 773 issue: 10 year: 2004 ident: 10.1016/j.vaccine.2024.04.045_b0150 article-title: Fatal transplacental infection with non-typhoidal Salmonella publication-title: Scand J Infect Dis doi: 10.1080/00365540410020802a – ident: 10.1016/j.vaccine.2024.04.045_b0680 – volume: 15 start-page: 452 issue: 7 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0200 article-title: Genetic susceptibility to invasive Salmonella disease publication-title: Nat Rev Immunol doi: 10.1038/nri3858 – volume: 13 start-page: 400 year: 2014 ident: 10.1016/j.vaccine.2024.04.045_b0450 article-title: The association between malaria and non-typhoid Salmonella bacteraemia in children in sub-Saharan Africa: a literature review publication-title: Malar J doi: 10.1186/1475-2875-13-400 – volume: 21 start-page: 529 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2024.04.045_b0055 article-title: Geographical distribution of risk factors for invasive non-typhoidal Salmonella at the subnational boundary level in sub-Saharan Africa publication-title: BMC Infect Dis doi: 10.1186/s12879-021-06198-1 – volume: 69 start-page: S459 issue: Suppl 6 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0335 article-title: A multicenter cost-of-illness and long-term socioeconomic follow-up study in the Severe Typhoid Fever in Africa Program: study protocol publication-title: Clin Infect Dis doi: 10.1093/cid/ciz608 – volume: 3 issue: 1501 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0195 article-title: Cross-sectional study of IgG antibody levels to invasive nontyphoidal Salmonella LPS O-antigen with age in Uganda publication-title: Gates Open Res – volume: 9 start-page: 20310 issue: 1 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0310 article-title: Distinct climate influences on the risk of typhoid compared to invasive non-typhoid Salmonella disease in Blantyre, Malawi publication-title: Sci Rep doi: 10.1038/s41598-019-56688-1 – ident: 10.1016/j.vaccine.2024.04.045_b0315 – ident: 10.1016/j.vaccine.2024.04.045_b0655 – volume: 399 start-page: 629 issue: 10325 year: 2022 ident: 10.1016/j.vaccine.2024.04.045_b0265 article-title: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis publication-title: Lancet doi: 10.1016/S0140-6736(21)02724-0 – volume: 20 start-page: 619 issue: 6 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0435 article-title: Companion and complementary diagnostics for infectious diseases publication-title: Expert Rev Mol Diagn doi: 10.1080/14737159.2020.1724784 – volume: 61 start-page: S310 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0465 article-title: Emergence of community-acquired, multidrug-resistant invasive nontyphoidal Salmonella disease in rural Western Kenya, 2009–2013 publication-title: Clin Infect Dis doi: 10.1093/cid/civ674 – ident: 10.1016/j.vaccine.2024.04.045_b0500 – volume: 23 start-page: 520 issue: 6 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0545 article-title: Opsonophagocytic assay to evaluate immunogenicity of nontyphoidal Salmonella vaccines publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00106-16 – ident: 10.1016/j.vaccine.2024.04.045_b0565 doi: 10.1007/82_2021_246 – volume: 18 start-page: 212 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0275 article-title: Invasive non-typhoidal Salmonella infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment publication-title: BMC Med doi: 10.1186/s12916-020-01652-4 – volume: 13 issue: 10 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0065 article-title: Supporting evidence for a human reservoir of invasive non-Typhoidal Salmonella from household samples in Burkina Faso publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0007782 – volume: 6 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0350 article-title: Diagnostic bacteriology in district hospitals in sub-Saharan Africa: at the forefront of the containment of antimicrobial resistance publication-title: Front Med doi: 10.3389/fmed.2019.00205 – ident: 10.1016/j.vaccine.2024.04.045_b0610 – volume: 22 start-page: 918 issue: 1 year: 2023 ident: 10.1016/j.vaccine.2024.04.045_b0640 article-title: The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2023.2270596 – volume: 219 start-page: 295 issue: 2 year: 2019 ident: 10.1016/j.vaccine.2024.04.045_b0190 article-title: The role of maternally acquired antibody in providing protective immunity against nontyphoidal Salmonella in urban Vietnamese infants: a birth cohort study publication-title: J Infect Dis doi: 10.1093/infdis/jiy501 – volume: 9 issue: 7 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0100 article-title: Modelling the contributions of malaria, HIV, malnutrition and rainfall to the decline in paediatric invasive non-typhoidal Salmonella disease in Malawi publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0003979 – ident: 10.1016/j.vaccine.2024.04.045_b0570 – volume: 374 start-page: 1364 issue: 9698 year: 2009 ident: 10.1016/j.vaccine.2024.04.045_b0090 article-title: Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study publication-title: Lancet doi: 10.1016/S0140-6736(09)61374-X – volume: 34 start-page: 2907 year: 2016 ident: 10.1016/j.vaccine.2024.04.045_b0590 article-title: Nontyphoidal Salmonella disease: current status of vaccine research and development publication-title: Vaccine doi: 10.1016/j.vaccine.2016.03.072 – volume: 14 issue: 1 year: 2024 ident: 10.1016/j.vaccine.2024.04.045_b9000 article-title: Protocol for the challenge non-typhoidal Salmonella (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK publication-title: BMJ Open doi: 10.1136/bmjopen-2023-076477 – volume: 61 start-page: S266 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0560 article-title: Control of invasive Salmonella disease in Africa: is there a role for human challenge models? publication-title: Clin Infect Dis doi: 10.1093/cid/civ673 – volume: 61 start-page: S235 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0380 article-title: A perspective on invasive Salmonella disease in Africa publication-title: Clin Infect Dis doi: 10.1093/cid/civ709 – volume: 24 start-page: e00057 issue: 7 year: 2017 ident: 10.1016/j.vaccine.2024.04.045_b0215 article-title: Loss of humoral and cellular immunity to invasive nontyphoidal Salmonella during current or convalescent Plasmodium falciparum infection in Malawian children publication-title: Clin Vaccine Immunol CVI doi: 10.1128/CVI.00057-17 – volume: 61 start-page: S272 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0155 article-title: Clinical and microbiological features of Salmonella meningitis in a South African population, 2003–2013 publication-title: Clin Infect Dis doi: 10.1093/cid/civ685 – volume: 61 start-page: S363 issue: Suppl 4 year: 2015 ident: 10.1016/j.vaccine.2024.04.045_b0105 article-title: Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014 publication-title: Clin Infect Dis doi: 10.1093/cid/civ691 – ident: 10.1016/j.vaccine.2024.04.045_b0505 – volume: 11 issue: 2 year: 2017 ident: 10.1016/j.vaccine.2024.04.045_b0370 article-title: Modeling the potential for vaccination to diminish the burden of invasive non-typhoidal Salmonella disease in young children in Mali, West Africa publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0005283 – ident: 10.1016/j.vaccine.2024.04.045_b0635 – volume: 71 start-page: S248 issue: Suppl 3 year: 2020 ident: 10.1016/j.vaccine.2024.04.045_b0400 article-title: Healthcare utilization patterns for acute febrile illness in Bangladesh, Nepal, and Pakistan: results from the Surveillance for Enteric Fever in Asia Project publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1321 – ident: 10.1016/j.vaccine.2024.04.045_b0555 doi: 10.12688/wellcomeopenres.19012.1 |
| SSID | ssj0005319 |
| Score | 2.4653475 |
| Snippet | Invasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in sub-Saharan Africa... AbstractInvasive non-typhoidal Salmonella (iNTS) disease is an under-recognized high-burden disease causing major health and socioeconomic issues in... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S101 |
| SubjectTerms | Africa South of the Sahara - epidemiology Allergy and Immunology antibiotic resistance Antimicrobial agents Antimicrobial resistance Bacteremia Clinical trials Combined vaccines Comorbidity Development strategies Disease prevention Drug resistance Epidemiology Fever Genotypes HIV HIV infections Human immunodeficiency virus Humans Illnesses Infants Infections iNTS Invasive non-typhoidal Salmonella Malaria Malnutrition Meningitis Nonprofit organizations Organizations Pathogens Population-based studies Public health Public private partnerships Quality control R&D Research & development research and development Risk factors Salmonella Salmonella Enteritidis Salmonella enteritidis - genetics Salmonella enteritidis - immunology Salmonella enteritidis - pathogenicity Salmonella Infections - epidemiology Salmonella Infections - immunology Salmonella Infections - microbiology Salmonella Infections - prevention & control Salmonella Typhi Salmonella Typhimurium Salmonella typhimurium - genetics Salmonella typhimurium - immunology Salmonella typhimurium - pathogenicity Salmonella Vaccines - administration & dosage Salmonella Vaccines - immunology serotypes social benefit stakeholders Sub-Saharan Africa Surveillance therapeutics Tropical diseases Typhoid Vaccine Vaccine development Vaccine value profile Vaccines Virulence World Health Organization |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB7alJZCKa372jYtKpSc4sSWbcl7KiU0hEJKIA98E7Ik04Tg3cSbwP77zliyfUmTwp52PStZI818mifAt0xrq1NTxjpxZZwLjnJQGh0bkWTGiEyYhhKcD3-Lg9P8V1VUweDWhbDKQSb2gtouDNnId3EvkpUCNdL35VVMXaPIuxpaaDyGJ33pMtzPspJTiEfWN_bAa0Ye52lSTRk8uxc7t9qQ6xqviDzvq51SRtPduulf2LPXQfuv4GUAj-yH5_ZreOTaCJ76dpLrCJ4dBkd5BFtHviT1epudTBlW3TbbYkdTsWqkeeHtdsynI0UQnVF8TJ-ky4a_ewN7Z_41GNUGdyw0-mYIeNl5e6spBJ61izZerZd_FucW53isL3HFKLSKBR_QWzjd_3mydxCH9guxKbJiFSNUQCxXzLm287kVNUdoJZDlvC5qaTLbNJx6FRttESVy7aRobCbwvog6X6LUzN7BBg7tPgCztnS6MbVF8IUKMC112TQOafBLa42cQT4svDKhNjm1yLhUQxDahQr8UsQvldCnmMHOSLb0xTkeIhADV9WQeYqyUqH6eIhQ3kXounDiO5WqjqtEHSc9wkwqis3NZYKU5UgZQI0HK_8z6Oaw8dQ4znQOZvB1_BllAjl6dOsWN_4ZSljmxT3PoKoTZZoXyQze-009rmE272_K8uP9E_gEz2m2ZOnmxSZsrK5v3GeEaKv6S38O_wJgFzqR priority: 102 providerName: ProQuest |
| Title | Vaccine value profile for invasive non-typhoidal Salmonella disease |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X24004705 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X24004705 https://dx.doi.org/10.1016/j.vaccine.2024.04.045 https://www.ncbi.nlm.nih.gov/pubmed/39003017 https://www.proquest.com/docview/3079783218 https://www.proquest.com/docview/3079956125 https://www.proquest.com/docview/3153681450 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-6lI29jC378tYNDUaf6sSWbdl-7EJLttEQ1g_yJmRJpinFCUtayMv-9t3ZssNYt45BcPyhQ0J3vvvJug-Aj5FSRoU681VgMz8WHPVgqpWvRRBpLSKhSwpwPpmI8Xn8ZZbMdmDUxsKQW6XT_Y1Or7W1uzN0szlczufD06C25cGMvCDjlPKY7vIoF0kPdg8_fx1Ptp4eUV3fg9r7RLAN5BleDW6Vph1sXCnyuE56SoFNd5uoP0HQ2hQdP4UnDkOyw2aYz2DHVn142FSV3PTh0YnbL-_D_rTJTL05YGfbQKvVAdtn023OaqTpX5BbTB2by1ry5zC6aIbNKCW4Za6-N0Ocy-bVrSLPd1YtKn-9WV4u5gbHdKquUa7Jo4q5rZ8XcH58dDYa-67qgq-TKFn7iBAQwiU5VybPjSg4IiqBnOZFUqQ6MmXJqUSxVgbBIVc2FaWJBC4T0dSnqCyjl9DDru1rYMZkVpW6MMgntHthprKytEiDN43RqQdxO9FSu5TkVBnjWra-Z1fS8UcSf2RAv8SDQUe2bHJy3EcgWi7KNuAUVaREq3EfYXoXoV25F30lQ7niMpC_CaMHWUf5izz_S6d7raDJrh9UxfSRDgGZBx-6x6gKaH9HVXZx07ShOGWe_KUNWjiRhXESePCqEeJuDqO8XiCnb_5_7G_hMV3Rx2-e7EFv_f3GvkPUti7ew4PBjxCP6SzFYzbC8-Y9xf9PR5Ppt58SyEVX |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVDwkhCC8AgUWCXqqW2dtr50DQlBapbSJIppWuS3r3bVoVTmBpEX5U_xGZrx-XErLpZJPtse79oxnvtmdB8C7QCmjujrxlG8TLxQc9WCslaeFH2gtAqEzSnAeDEX_KPw6iSYr8KfKhaGwykonForaTDWtkW-hLNIqBVqkj7OfHnWNot3VqoWGE4t9u_yNLtv8w94X5O97znd3xtt9r-wq4OkoiBYeWkCEKFGPK9PrGZFyRAwC34SnURrrwGQZpxa8WhkEP1zZWGQmEOgGoSmLURkE-NxbsBpSRmsLVj_vDEffmqCSoGglgo5N6IVdf9LkDG2dbl4oTZvl6JTysKivSjlUl1vDf6HdwurtPoQHJVxln5x8PYIVm7fhtmtguWzDnUG5Nd-G9ZErgr3cYOMmp2u-wdbZqCmPjTT33UohcwlQbWgfU0ROkRbMqsc9hu1j9xqMqpFbVrYWZwix2Ul-oSjonuXT3FssZz-mJwbneKjOkEcUzMXKXacncHQjrHkKLRzaPgdmTGJVplODcA9NbjdRSZZZpMGTxui4A2H14aUuq6FTU44zWYW9ncqSX5L4JX06og5s1mQzVw7kOgJRcVVWua6onSUarOsI48sI7bzUMXPZlXMufXnoF5jWn1A0cBj7SJnUlCWMcvDofwZdqwRP1uM0f14H3taXUQvR1pLK7fTc3UMp0jy64h40riLphpHfgWdOqOtvGPQK3zx-cfUE3sDd_nhwIA_2hvsv4R7NnNbZebQGrcWvc_sKAeIifV3-lQy-37Qi-AtPPXho |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NISYkhKB8rDDASLCnZU2cxE4fEEIb1cbYVGkfyptxbEfbNLWFdkP91_jruIuT5mVsvEzqU5qLnZx99zvfF8CHWGurI5MFOnRZkAiOclAaHRgRxsaIWJiSEpz3D8TOcfItT_Ml-NPkwlBYZSMTK0Ftx4bOyHu4FumUAjVSr6zDIobbg8-TnwF1kCJPa9NOwy-RPTf_jebb9NPuNvL6I-eDr0dbO0HdYSAwaZzOAtSGCFfSPte237ei4IgeBL4VL9JCmtiWJad2vEZbBEJcOylKGws0iVCtSRQMMT73HtyXMaIq3Esyl214SVw1FUETJwmSKMzb7KHe-eaVNuQ2R_OUJ1WlVcqmul4v_gv3Vvpv8AQe18CVffEr7SksuVEHHvhWlvMOrOzXTvoOrA99Oez5Bjtqs7umG2ydDdtC2UjzyJ8ZMp8K1YHOCcXmVAnCrHncM9g68a_BqC65Y3WTcYZgm52NrjSF37PReBTM5pPT8ZnFOR7qC-QQhXWx2v_0HI7vhDEvYBmHdqvArM2cLk1hEfih8o0ynZWlQxq8aK2RXUiaD69MXRed2nNcqCYA7lzV_FLELxXSL-3C5oJs4guD3EYgGq6qJusV5bRC1XUbobyO0E1raTNVkZpyFarDsEK3YU5xwYkMkTJbUNaAygOl_xl0rVl4ajFOuwe78H7xN8ojcjLpkRtf-nsoWZqnN9yDalZkUZKGXXjpF_XiG8b9ykqXr26ewDtYwe2vvu8e7L2GhzRxOnDn6Rosz35dujeIFGfF22pLMvhx1zLgL3U_ey8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccine+value+profile+for+invasive+non-typhoidal+Salmonella+disease&rft.jtitle=Vaccine&rft.au=Martin%2C+Laura+B.&rft.au=Tack%2C+Bieke&rft.au=Marchello%2C+Christian+S.&rft.au=Sikorski%2C+Michael+J.&rft.date=2024-07-25&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=42&rft.issue=19&rft.spage=S101&rft.epage=S124&rft_id=info:doi/10.1016%2Fj.vaccine.2024.04.045&rft.externalDocID=S0264410X24004705 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X24X00213%2Fcov150h.gif |